Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Testing in Breast Cancer: Assessing the Value of Repeated Centralized Testing in Excision Specimens

被引:2
|
作者
Hariri, Nosaibah [1 ]
Hasteh, Farnaz [1 ]
Walavalkar, Vighnesh [1 ]
Roma, Andres A. [1 ]
Fadare, Oluwole [1 ]
机构
[1] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA
关键词
repeat testing; estrogen receptor; progesterone receptor; human epidermal growth factor receptor-2; IN-SITU HYBRIDIZATION; INTRATUMORAL HETEROGENEITY; CORE-NEEDLE; CLINICAL ONCOLOGY/COLLEGE; PROTEIN EXPRESSION; AMERICAN SOCIETY; HER2; DISCORDANCE; ER; RECOMMENDATIONS;
D O I
10.1097/PAI.0000000000000525
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
At some tertiary breast care centers, where many patients are referred from other institutions, it is routine to repeat testing for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2/neu) in excision specimens if these tests were performed on the preceding biopsy at the referring facility. The goal of this study is to assess the value of this practice. We documented results from ER, PR, and HER2 testing in 541 consecutive invasive breast cancers excised over a 2.5-year period and analyzed the subset (n=153) for which testing was performed on the excision specimen solely due to the fact that testing on the preceding biopsy was performed at an outside institution. The rates and directions of biopsy-to-excision change were as follows: ER [1.3% (2/153), 100% from (+) to (-)]; PR [4% (6/153), 83% from (+) to (-)]; HER2/neu assessed by immunohistochemistry [21% (29/137)]; HER2/neu assessed by fluorescence in situ hybridization [3.3% (2/61); 50% from amplified to nonamplified and 50% vice versa]. There were no ER(-) and PR(-) biopsy cases that became ER and/or PR(+) in the excision. By coordinate analysis for the hormone receptors [ie, ER and/or PR(+) being indicative of "hormone receptor" (HR) positivity], there were no cases that changed from HR(+) in the biopsy to HR(-) in the excision (or vice versa), which suggests that repeat testing for ER and PR in this setting is of limited value. In an analysis that incorporated both immunohistochemistry and in situ fluorescence hybridization results, there were 2 cases with a clinically significant biopsy-to-excision change in HER2/neu status in which that change was detected primarily because the excision was retested. These findings provide baseline data for formulating policies on whether repeat testing should routinely be performed in the described scenario.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [31] Characterization of Estrogen Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
    Li, Ming
    Lv, Hong
    Shui, Ruohong
    Lu, Hongfen
    Yang, Wentao
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 151 - 151
  • [32] ER, PR, and HER2/neu Testing in Breast Cancer: Quantifying the Value of Repeated Centralized Testing in Excision Specimens
    Hariri, Nosaibah
    Roma, Andres A.
    Hasteh, Farnaz
    Walavalkar, Vighnesh
    Fadare, Oluwole
    LABORATORY INVESTIGATION, 2017, 97 : 45A - 46A
  • [33] Correlation of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) expression as predicted by core biopsy with the immunohistochemical results of surgical breast cancer specimens
    Erggelet, Julian
    Grosse, Regina
    Holzhausen, Hans-Juergen
    Hauptmann, Steffen
    Thomssen, Christoph
    BREAST CARE, 2007, 2 (02) : 94 - 98
  • [34] ER, PR, and HER2/neu Testing in Breast Cancer: Quantifying the Value of Repeated Centralized Testing in Excision Specimens
    Hariri, Nosaibah
    Roma, Andres A.
    Hasteh, Farnaz
    Walavalkar, Vighnesh
    Fadare, Oluwole
    MODERN PATHOLOGY, 2017, 30 : 45A - 46A
  • [35] Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in invasive breast cancer in women
    Badowska-Kozakiewicz, Anna M.
    Sobol, Maria
    Patera, Janusz
    Kozlowski, Wojciech
    ARCHIVES OF MEDICAL SCIENCE, 2013, 9 (03) : 466 - 471
  • [36] Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer
    Chen, Mengdi
    Wu, Jiayi
    Liu, Deyue
    Chen, Weilin
    Lin, Caijin
    Andriani, Lisa
    Ding, Shuning
    Huang, Ou
    He, Jianrong
    Chen, Xiaosong
    Chen, Weiguo
    Li, Yafen
    Shen, Kunwei
    Zhu, Li
    CLINICAL BREAST CANCER, 2022, 22 (02) : E147 - E156
  • [37] Estrogen Receptor and Receptor Tyrosine Kinase Signaling: Use of Combinatorial Hormone and Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2-Targeted Therapies for Breast Cancer
    Zabransky, Daniel J.
    Park, Ben Ho
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) : 1084 - 1086
  • [38] Human epidermal growth factor receptor 2 testing recommendation - In reply
    Wolff, Antonio C.
    Hammond, M. Elizabeth H.
    Schwartz, Jared N.
    Hayes, Daniel F.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2007, 131 (09) : 1331 - 1333
  • [39] Human Epidermal Growth Factor Receptor 2 Testing in Primary Breast Cancer in the Era of Standardized Testing: A Canadian Prospective Study
    Hanna, Wedad M.
    Barnes, Penny J.
    Chang, Martin C.
    Gilks, C. Blake
    Magliocco, Anthony M.
    Rees, Henrike
    Quenneville, Louise
    Robertson, Susan J.
    SenGupta, Sandip K.
    Nofech-Mozes, Sharon
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (35) : 3967 - 3973
  • [40] Human epidermal growth factor receptor 2 testing recommendation - In reply
    Wolff, Antonio C.
    Hammond, M. Elizabeth H.
    Schwartz, Jared N.
    Hayes, Daniel F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 4021 - 4023